Cluj-Napoca

• An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Clarith … Ended
  2024-520153-21-00 2 2026-01-29 Infectious diseases
• A double blinded, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study comparing Bupr … Ended
  2024-516035-27-00 2 2026-01-09 major depressive illness
• A double blinded, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study comparing Bupr … Ended
  2024-516034-35-00 2 2025-12-05 major depressive illness
• An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Tamsulo … Ended
  2024-517642-34-00 2 2025-11-10 Benign prostatic hyperplasia (BPH)
• An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Tamsulo … Ended
  2024-517625-72-00 2 2025-10-16 Benign prostatic hyperplasia (BPH)
• An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Lisdexa … Ended
  2024-513517-12-00 2 2025-10-01 ADHD
• An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ruxolit … Ended
  2024-519801-36-00 2 2025-07-14 Myelofibrosis, polycythemia vera, acute and chronic graft-versus-host-
• A trial to learn how saruparib works and how safe it is in the bodies of adults with advanced solid tumors Ended
  2024-513692-41-00 3 2025-06-11 advanced solid malignancies
• A Study to Learn More About an Investigational Medicine called HDP-102 in Patients with Relapsed/Refractory B-cell Blood Cancers. Ended
  2023-508759-38-00 1 2025-06-04 Relapsed/Refractory B-cell Malignancies
• An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Naltrex … Ended
  2024-519776-20-00 2 2025-05-12 Alcohol dependence
• An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Enzalutam … Ended
  2024-518209-16-00 2 2025-04-14 Prostate cancer
• An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Enzalutam … Ended
  2024-518211-20-00 2 2025-04-14 Prostate cancer
• Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® … Ended
  2023-507865-24-00 5 2025-03-28 Advanced (unresectable/metastatic) melanoma
• An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Brivara … Ended
  2024-516500-42-00 2 2025-03-13 Epilepsy
• A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4 … Ended
  2024-516840-24-00 3 2025-03-05 Chronic Kidney disease
• Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated Ended
  2024-512505-66-00 10 2025-03-03 HIV-1 Infection
• An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Bosutinib … Ended
  2024-516489-12-00 2 2025-01-31 myeloid leukemia
• An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Dextroa … Ended
  2023-509874-48-00 2 2025-01-09 ADHD
• An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Lamotrigi … Ended
  2024-513106-62-00 2 2024-12-16 Bipolar disorder
• An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Empagli … Ended
  2024-513340-28-00 2 2024-11-19 Diabetes
• rIFN-Gamma 1b in Candidemia Ended
  2024-510816-55-00 4 2024-11-08 Candidemia
• An open label, balanced, randomized, two-treatment, four period, two-sequence, multiple-dose (steady-state), fully-replicate crossover bioeq … Ended
  2024-512770-10-00 2 2024-10-07 Rheumatoid arthritis, ulcerative colitis, atopic dermatitis, Crohn's d
• A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally In … Ended
  2023-508603-21-00 4 2024-09-20 Venous Thromboembolism
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in adult participants with severe … Ended
  2024-511225-64-00 4 2024-09-18 Alopecia areata

Showing 361–384 of 473 trials